Clinical stage drug development company Telik has reported a net loss of $1.88m, or $0.78 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.85m, or $1.58 per share, for the third quarter ended 30 ...
Tags: Clinical stage drug development, net loss, loss from operations